The Stargardt Disease Therapeutics Market, estimated at USD 488.7 Mn in 2025, is expected to exhibit a CAGR of 31.7% and reach USD 3,358.5 Mn by 2032.
The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.
Key market players are focusing on adoption of growth strategies such as launch of new products, and this is expected to drive the global stargardt disease therapeutics market growth. For instance, on August 21, 2025, according to the 2025 annual report published by Ocugen, Inc., a biotechnology company, the Phase I/II trials for Ocugen’s gene therapies named OCU410 and OCU410ST are planned for initiation by the end of 2025 in geographic atrophy and Stargardt disease.
Global Stargardt Disease Therapeutics Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2025, as "coronavirus disease 2025" or COVID-19. This virus spreads quicklys and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems with regard to the transportation of things from one place to another.
Global Stargardt Disease Therapeuticss Market: Key Developments
On March 01, 2025, according to 2025 annual report published by IVERIC bio, Inc., a science-driven biopharmaceutical company, the patient enrollment in STAR, the company’s Phase 2b screening clinical trial of ACP for the treatment of autosomal recessive stargardt disease (STGD1), is ongoing.
In October 2025, Apple Tree Partners, a leader in life sciences venture capital, announced the launch of Ascidian Therapeutics, a biotechnology company that is built and developed by ATP and funded with a US$ 50 million Series A financing. With focus on treating human diseases by replacing mutated exons at the RNA level, Ascidian's technology enables therapeutic targeting of large genes and genes with high mutational variance while maintaining native gene expression patterns and levels. This approach is designed to provide the durability of gene therapy while reducing risks associated with DNA editing and manipulation. Ascidian is advancing its lead program for ABCA4 retinopathy in IND-enabling studies while it progresses its pipeline of programs in ophthalmology, and neurological, neuromuscular, and rare diseases.